Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322850 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
A Phase 1 study of Acute Myeloid Leukemia and Mixed Phenotype Acute Leukemia, sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT05322850 is a Phase 1 study of Acute Myeloid Leukemia and Mixed Phenotype Acute Leukemia that is actively recruiting participants, run by University of Florida. The registered enrollment target is 40 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (66% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT05322850, a Phase 1 study of Acute Myeloid Leukemia and Mixed Phenotype Acute Leukemia, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
Conditions Studied
Interventions
- BIOLOGICAL Orca-Q
Study Locations (4)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
- Nicklaus Children's Hospital - Miami
- Johns Hopkins All Children's Hospital - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05322850
The ClinicalTrials.gov registry entry for NCT05322850 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (66% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Orca-Q is the first listed.
NCT05322850 reports 4 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05322850 about?
NCT05322850 is a clinical study titled "Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)". This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malignancies.
What is the current status of trial NCT05322850?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-08-16. Estimated completion is 2027-09.
What conditions does trial NCT05322850 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Acute Lymphoid Leukemia, Chronic Myeloid Leukemia - Accelerated Phase.
What interventions are being tested in trial NCT05322850?
The interventions under investigation include: Orca-Q (BIOLOGICAL).
Who is sponsoring clinical trial NCT05322850?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05322850 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.